Cargando…
Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center
BACKGROUND: Acromegaly is a rare, slowly progressive disorder resulting from excessive growth hormone (GH) production by a pituitary somatotroph tumor. The objective of this study was to examine acromegaly treatment outcomes during long-term care at a specialized pituitary center in patients present...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545017/ https://www.ncbi.nlm.nih.gov/pubmed/28778166 http://dx.doi.org/10.1186/s12902-017-0199-x |
_version_ | 1783255350359621632 |
---|---|
author | Carmichael, John D. Broder, Michael S. Cherepanov, Dasha Chang, Eunice Mamelak, Adam Said, Qayyim Neary, Maureen P. Bonert, Vivien |
author_facet | Carmichael, John D. Broder, Michael S. Cherepanov, Dasha Chang, Eunice Mamelak, Adam Said, Qayyim Neary, Maureen P. Bonert, Vivien |
author_sort | Carmichael, John D. |
collection | PubMed |
description | BACKGROUND: Acromegaly is a rare, slowly progressive disorder resulting from excessive growth hormone (GH) production by a pituitary somatotroph tumor. The objective of this study was to examine acromegaly treatment outcomes during long-term care at a specialized pituitary center in patients presenting with lack of biochemical control. METHODS: Data came from an acromegaly registry at the Cedars-Sinai Medical Center Pituitary Center (center). Acromegaly patients included in this study were those who presented biochemically-uncontrolled for care at the center. Biochemical control status, based on serum insulin-like growth factor-1 values, was determined at presentation and at study end. Patient characteristics and acromegaly treatments were reported before and after presentation by presenting treatment status and final biochemical control status. Data on long-term follow-up were recorded from 1985 through June 2013. RESULTS: Seventy-four patients presented uncontrolled: 40 untreated (54.1%) and 34 (45.9%) previously-treated. Mean (SD) age at diagnosis was 43.2 (14.7); 32 (43.2%) were female patients. Of 65 patients with tumor size information, 59 (90.8%) had macroadenomas. Prior treatments among the 34 previously-treated patients were pituitary surgery alone (47.1%), surgery and medication (41.2%), and medication alone (11.8%). Of the 40 patients without prior treatment, 82.5% achieved control by study end. Of the 34 with prior treatment, 50% achieved control by study end. CONCLUSIONS: This observational study shows that treatment outcomes of biochemically-uncontrolled acromegaly patients improve with directed care, particularly for those that initially present untreated. Patients often require multiple modalities of treatment, many of which are offered with the highest quality at specialized pituitary centers. Despite specialized care, some patients were not able to achieve biochemical control with methods of treatment that were available at the time of their treatment, showing the need for additional treatment options. |
format | Online Article Text |
id | pubmed-5545017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55450172017-08-07 Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center Carmichael, John D. Broder, Michael S. Cherepanov, Dasha Chang, Eunice Mamelak, Adam Said, Qayyim Neary, Maureen P. Bonert, Vivien BMC Endocr Disord Research Article BACKGROUND: Acromegaly is a rare, slowly progressive disorder resulting from excessive growth hormone (GH) production by a pituitary somatotroph tumor. The objective of this study was to examine acromegaly treatment outcomes during long-term care at a specialized pituitary center in patients presenting with lack of biochemical control. METHODS: Data came from an acromegaly registry at the Cedars-Sinai Medical Center Pituitary Center (center). Acromegaly patients included in this study were those who presented biochemically-uncontrolled for care at the center. Biochemical control status, based on serum insulin-like growth factor-1 values, was determined at presentation and at study end. Patient characteristics and acromegaly treatments were reported before and after presentation by presenting treatment status and final biochemical control status. Data on long-term follow-up were recorded from 1985 through June 2013. RESULTS: Seventy-four patients presented uncontrolled: 40 untreated (54.1%) and 34 (45.9%) previously-treated. Mean (SD) age at diagnosis was 43.2 (14.7); 32 (43.2%) were female patients. Of 65 patients with tumor size information, 59 (90.8%) had macroadenomas. Prior treatments among the 34 previously-treated patients were pituitary surgery alone (47.1%), surgery and medication (41.2%), and medication alone (11.8%). Of the 40 patients without prior treatment, 82.5% achieved control by study end. Of the 34 with prior treatment, 50% achieved control by study end. CONCLUSIONS: This observational study shows that treatment outcomes of biochemically-uncontrolled acromegaly patients improve with directed care, particularly for those that initially present untreated. Patients often require multiple modalities of treatment, many of which are offered with the highest quality at specialized pituitary centers. Despite specialized care, some patients were not able to achieve biochemical control with methods of treatment that were available at the time of their treatment, showing the need for additional treatment options. BioMed Central 2017-08-04 /pmc/articles/PMC5545017/ /pubmed/28778166 http://dx.doi.org/10.1186/s12902-017-0199-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Carmichael, John D. Broder, Michael S. Cherepanov, Dasha Chang, Eunice Mamelak, Adam Said, Qayyim Neary, Maureen P. Bonert, Vivien Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center |
title | Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center |
title_full | Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center |
title_fullStr | Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center |
title_full_unstemmed | Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center |
title_short | Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center |
title_sort | long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545017/ https://www.ncbi.nlm.nih.gov/pubmed/28778166 http://dx.doi.org/10.1186/s12902-017-0199-x |
work_keys_str_mv | AT carmichaeljohnd longtermtreatmentoutcomesofacromegalypatientspresentingbiochemicallyuncontrolledatatertiarypituitarycenter AT brodermichaels longtermtreatmentoutcomesofacromegalypatientspresentingbiochemicallyuncontrolledatatertiarypituitarycenter AT cherepanovdasha longtermtreatmentoutcomesofacromegalypatientspresentingbiochemicallyuncontrolledatatertiarypituitarycenter AT changeunice longtermtreatmentoutcomesofacromegalypatientspresentingbiochemicallyuncontrolledatatertiarypituitarycenter AT mamelakadam longtermtreatmentoutcomesofacromegalypatientspresentingbiochemicallyuncontrolledatatertiarypituitarycenter AT saidqayyim longtermtreatmentoutcomesofacromegalypatientspresentingbiochemicallyuncontrolledatatertiarypituitarycenter AT nearymaureenp longtermtreatmentoutcomesofacromegalypatientspresentingbiochemicallyuncontrolledatatertiarypituitarycenter AT bonertvivien longtermtreatmentoutcomesofacromegalypatientspresentingbiochemicallyuncontrolledatatertiarypituitarycenter |